Premium
Induced remission of malignant melanoma with actinomycin D. Immunologic implications
Author(s) -
Golomb Frederick M.,
Solowey Alex C.,
Postel Allen,
Gumport Stephen L.,
Wright Jane C.
Publication year - 1967
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(1967)20:5<656::aid-cncr2820200513>3.0.co;2-l
Subject(s) - melanoma , medicine , antigen , perfusion , chemotherapy , regression , toxicity , oncology , gastroenterology , pathology , immunology , cancer research , psychology , psychoanalysis
Five patients with malignant melanoma of the extremities experienced tumor regression while being treated with intravenous actinomycin D. Each had responded to a prior isolated perfusion with actinomycin D with transient tumor regression and drug toxicity in the perfused limb. Three patients are free of demonstrable melanoma for more than 4 1/2 years. These patients exhibited intense delayed skin hypersensitivity to test antigens; however, patients with melanoma exhibited a greater sensitivity to these antigens than did patients with carcinoma. Two other patients died of metastases to the brain without recurrent melanoma elsewhere. Five other patients similarly treated did not respond with tumor regression. No similar regression of melanoma has been observed in 23 patients treated with actinomycin D alone or among 101 other patients treated with 18 other chemotherapeutic agents.